An ongoing phase I study (NCT06607185) is assessing the safety and tolerability of LY4066434, a pan-KRAS inhibitor, in patients with KRAS-mutant advanced or metastatic solid tumors, including CCA (Table 4). The gene discussed is KRAS; the disease is cholangiocarcinoma.